1. Васильев В.И., Грачев Ю.В., Никитин С.С. Поражение периферической и центральной нервной системы при болезни Шегрена. Клинические и теоретические аспекты боли. М.: Издательство РУДН, 2001.[Vasiliev VI, Grachev UV, Nikitin SS. Porazhenie perifericheskoi i tsentralʼnoi nervnoi sistemy pri bolezni shegrena. klinicheskie i teoreticheskie aspekty boly. Moscow: RUDN Press; 2001. (In Russ.)].
2. Chai J, Logigian EL. Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol. 2010; 23: 509-13. http://doi.org/10. 1097/WCO.0b013e32833de6ab
3. Сафонова Т.Н., Васильев В.И., Лихванцева В.Г. Синдром Шегрена: руководство для врачей. М.: Издательство Московского университета; 2013.[Safonova TN, Vasiliev VI, Likhvantseva VG.  Sindrom Shegrena: rukovodstvo dlya vrachei. Moscow: Moscow University Press; 2013. (In Russ.)].
4. Massara A, Bonazza S, Castellino G et al. Central nervous system involvement in Sjogren’s syndrome: Unusual, but not unremarkable–clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology. 2010; 49(8): 1540-1549. https://doi.org/10.1093/rheumatology/keq111
5. Vincent TL, Richardson MP, Mackworth-Young CG, Hawke, Venables PJW. Sjogren’s syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med. 2003; 114:145-8. https://doi.org/10.1016/S0002-9343(02)01380-3
6. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF and Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485-1489.  http://doi.org/10.1212/01.wnl. 0000216139. 44259.74
7. Akaishi T, Nakashima I. Neuromyelitis Optica Spectrum Disorders. Neuroimaging Clin N Am. 2017 May; 27(2): 251-265. http://doi.org/ 10.1016/j.nic.2016.12.010
8. Lennon VA, Wingerchuck DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-2112. http://doi.org/10.1016/S0140-6736(04) 17551-X
9. Min JH, Kim HJ, Kim BJ et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler. 2009; 15:1069–1076. https://doi.org/ 10.1177/1352458509106228 
10. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple Sclerosis J. 2012; 18(1): 5-10. https://doi.org/10. 1177/1352458511431077
11. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S  et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren ’ s syndrome. Arthritis Rheum. 2010; 62(4):1198-200. https://doi.org/ 10.1002/ art.27337
12. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003; 60(5):848-53. https://doi.org/10.1212/01.WNL.0000049912.02954.2C
13. Ананьева Л.П., Соловьев С.К., Бекетова Т.В., Васильев В.И., Антелава О.А., Александрова Е.Н., Конева О.А., Цанян М.Э., Десинова О.В., Логвиненко О.А., Волков А.В., Хелковская-Сергеева А.Н., Новиков А.А., Алексанкин А.А., Насонов Е.Л. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014; 52(5):495-506. [Ananieva LP, Soloviyov SK, Beketova TV, Vasiliev VI, Antelava OA, Aleksandrova EN, Koneva OA, Tsanyan ME, Desinova OV, Logvinenko OA, Volkov AV, Helkovskaya-Sergeeva AN, Novikov AA, Aleksankin AA, Nasonov YL. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Rheumatology Science and Practice. 2014; 52(5):495-506. (In Russ.)]. https://doi.org/10. 14412/1995-4484-2014-495-506
14. Jahnke K, Thiel E. Treatment options for central nervous system lymphomas in immunocompetent patients. Expert Rev Neurother. 2009 Oct;9(10):1497-509. https://doi.org/10.1586/ern.09.100
15. Batchelor T, Grossman S, Mikkelsen T, Ye X, Desideri S,  Lesser G.  Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011; 76:929-930. http://doi.org/10. 1212/WNL.0b013e31820f2d94
16. Carvalho DC, Tironi TS, Freitas DS. Sjögren syndrome and neuromyelitis optica spectrumdisorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr. 2014 Aug; 72(8):619-24. http://doi.org/10. 1590/0004-282X20140097
17. Javed A, Balabanov R, Arnason BG. Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis. Mult Scler. 2008; 14:809-814. https://doi.org/10.1177/1352458508088941
18. Delporte C, Steinfeld S. Distribution and roles of aquaporins in salivary glands. Biochim Biophys Acta. 2006; 1758:1061-1070. https://doi.org/10.1016/j.bbamem.2006.01.022
19. Sawada J, Orimoto R et al. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion. Multiple Sclerosis Journal. 2014; 20(10):1413-1416. https://doi.org/10. 1177/1352458514540834
20. Kim SM, Waters P, Vincent A et al. Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler. 2009; 15:1062-8. https://doi.org/10.1177/1352458509106636
21. Sellner J, Boggild M, Clanet M et al. EFNS guidelines on the diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17: 1019-1032. https://doi.org/10.1111/j.1468-1331.2010.03066.x
22. Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferre L et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016 Apr; 22(4):511-9. https://doi.org/10.1177/1352458515594042
23. Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015; 262: 2329-2335. https://doi.org/10.1007/s00415-015-7852-y
24. Kim S, Kim W, Li X, Jung I and Kim H.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68: 1412-1420. https://doi.org/10.1001/archneurol.2011. 154
25. Mealy M, Wingerchuk  D, Palace J, Greenberg B and Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014; 71: 324-330. https://doi.org/10.1001/jamaneurol.2013.5699
26. Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A. 1992 Haematological manifestations of primary Sjogren’s syndrome: a clinicopathological study. Q J Med. 1992; 83:547-54. https://doi.org/ 10.1016/S0031-3025(16)35939-6
27. Capsoni F, Sarzi-Puttini P, Zanella A. Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005; 7:208-14.  https://doi.org/ 10.1186/ar1803
28. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003; 121(6):913-8. https://doi.org/10.1046/j.1365-2141.2003.04385.x 
29. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005; 106(3):795-802. https://doi.org/10.1182/blood-2004-08-3198

________________________________________________

1. [Vasiliev VI, Grachev UV, Nikitin SS. Porazhenie perifericheskoi i tsentralʼnoi nervnoi sistemy pri bolezni shegrena. klinicheskie i teoreticheskie aspekty boly. Moscow: RUDN Press; 2001. (In Russ.)].
2. Chai J, Logigian EL. Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol. 2010; 23: 509-13. http://doi.org/10. 1097/WCO.0b013e32833de6ab
3. [Safonova TN, Vasiliev VI, Likhvantseva VG.  Sindrom Shegrena: rukovodstvo dlya vrachei. Moscow: Moscow University Press; 2013. (In Russ.)].
4. Massara A, Bonazza S, Castellino G et al. Central nervous system involvement in Sjogren’s syndrome: Unusual, but not unremarkable–clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology. 2010; 49(8): 1540-1549. https://doi.org/10.1093/rheumatology/keq111
5. Vincent TL, Richardson MP, Mackworth-Young CG, Hawke, Venables PJW. Sjogren’s syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med. 2003; 114:145-8. https://doi.org/10.1016/S0002-9343(02)01380-3
6. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF and Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485-1489.  http://doi.org/10.1212/01.wnl. 0000216139. 44259.74
7. Akaishi T, Nakashima I. Neuromyelitis Optica Spectrum Disorders. Neuroimaging Clin N Am. 2017 May; 27(2): 251-265. http://doi.org/ 10.1016/j.nic.2016.12.010
8. Lennon VA, Wingerchuck DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-2112. http://doi.org/10.1016/S0140-6736(04) 17551-X
9. Min JH, Kim HJ, Kim BJ et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler. 2009; 15:1069–1076. https://doi.org/ 10.1177/1352458509106228 
10. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple Sclerosis J. 2012; 18(1): 5-10. https://doi.org/10. 1177/1352458511431077
11. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S  et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren ’ s syndrome. Arthritis Rheum. 2010; 62(4):1198-200. https://doi.org/ 10.1002/ art.27337
12. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003; 60(5):848-53. https://doi.org/10.1212/01.WNL.0000049912.02954.2C
13. [Ananieva LP, Soloviyov SK, Beketova TV, Vasiliev VI, Antelava OA, Aleksandrova EN, Koneva OA, Tsanyan ME, Desinova OV, Logvinenko OA, Volkov AV, Helkovskaya-Sergeeva AN, Novikov AA, Aleksankin AA, Nasonov YL. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Rheumatology Science and Practice. 2014; 52(5):495-506. (In Russ.)]. https://doi.org/10. 14412/1995-4484-2014-495-506
14. Jahnke K, Thiel E. Treatment options for central nervous system lymphomas in immunocompetent patients. Expert Rev Neurother. 2009 Oct;9(10):1497-509. https://doi.org/10.1586/ern.09.100
15. Batchelor T, Grossman S, Mikkelsen T, Ye X, Desideri S,  Lesser G.  Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011; 76:929-930. http://doi.org/10. 1212/WNL.0b013e31820f2d94
16. Carvalho DC, Tironi TS, Freitas DS. Sjögren syndrome and neuromyelitis optica spectrumdisorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr. 2014 Aug; 72(8):619-24. http://doi.org/10. 1590/0004-282X20140097
17. Javed A, Balabanov R, Arnason BG. Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis. Mult Scler. 2008; 14:809-814. https://doi.org/10.1177/1352458508088941
18. Delporte C, Steinfeld S. Distribution and roles of aquaporins in salivary glands. Biochim Biophys Acta. 2006; 1758:1061-1070. https://doi.org/10.1016/j.bbamem.2006.01.022
19. Sawada J, Orimoto R et al. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion. Multiple Sclerosis Journal. 2014; 20(10):1413-1416. https://doi.org/10. 1177/1352458514540834
20. Kim SM, Waters P, Vincent A et al. Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler. 2009; 15:1062-8. https://doi.org/10.1177/1352458509106636
21. Sellner J, Boggild M, Clanet M et al. EFNS guidelines on the diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17: 1019-1032. https://doi.org/10.1111/j.1468-1331.2010.03066.x
22. Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferre L et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016 Apr; 22(4):511-9. https://doi.org/10.1177/1352458515594042
23. Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015; 262: 2329-2335. https://doi.org/10.1007/s00415-015-7852-y
24. Kim S, Kim W, Li X, Jung I and Kim H.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68: 1412-1420. https://doi.org/10.1001/archneurol.2011. 154
25. Mealy M, Wingerchuk  D, Palace J, Greenberg B and Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014; 71: 324-330. https://doi.org/10.1001/jamaneurol.2013.5699
26. Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A. 1992 Haematological manifestations of primary Sjogren’s syndrome: a clinicopathological study. Q J Med. 1992; 83:547-54. https://doi.org/ 10.1016/S0031-3025(16)35939-6
27. Capsoni F, Sarzi-Puttini P, Zanella A. Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005; 7:208-14.  https://doi.org/ 10.1186/ar1803
28. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003; 121(6):913-8. https://doi.org/10.1046/j.1365-2141.2003.04385.x 
29. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005; 106(3):795-802. https://doi.org/10.1182/blood-2004-08-3198

А.В. Торгашина, В.И. Васильев 

ФГБНУ  «Научно-исследовательский институт ревматологии им. В.А. Насоновой»,  Москва, Россия

________________________________________________

A.V. TORGASHINA, V.I. VASILYEV

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia